Clinical Trial: A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety Disorder

U.S., Aug. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07759128) titled 'A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety Disorder' on Aug. 06.

Brief Summary: This is a global, phase 3, randomized, double-blind, parallel-group, 3-arm, placebo-controlled, multicenter study designed to compare the efficacy, safety, and tolerability of fixed doses of SEP-363856 (50 and 75 milligrams per day [mg/day]) to placebo in adults at least 18 years of age with generalized anxiety disorder (GAD) over 8 weeks.

Study Start Date: July 28

Study Type: INTERVENTIONAL

Condition: Generalized Anxiety Disorder

Intervention: DRUG: SEP-363856

Oral tablet

OTHER: Placebo

Or...